Review Article

Pharmacological Treatment for Hepatopulmonary Syndrome

Ahad Eshraghian,¹ Amir A'lam Kamyab,¹ and Seung Kew Yoon²

¹ Department of Internal Medicine, Shiraz University of Medical Sciences, Shiraz, Iran

² Division of Hepato-Gastroenterology, Department of Internal Medicine, Kangnam St. Mary Hospital, Catholic University Medical College, Seoul, Republic of Korea

Correspondence should be addressed to Ahad Eshraghian; eshraghiana@yahoo.com

Received 25 April 2013; Revised 30 July 2013; Accepted 12 August 2013

Academic Editor: Kusum Kharbanda

Copyright © 2013 Ahad Eshraghian et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Aim. Hepatopulmonary syndrome is a pulmonary dysfunction in the context of liver cirrhosis characterized by arterial deoxygenation. Affected patients have increased morbidity and mortality, and many of them expire before undergoing liver transplantation. Therefore, finding medical therapy as a bridge to transplantation or as a final treatment is necessary. In this study, we aimed to review the current literature about pharmacological options available for treatment of hepatopulmonary syndrome. **Methods.** A PubMed and Scopus search was conducted in January 2013 on the English literature published in any time period to find human and animal studies reporting pharmacological therapy of hepatopulmonary syndrome. **Results.** Out of 451 studies, 29 relevant articles were included. The number of patients, type, dose, duration, and mechanism of drugs in these studies was extracted and summarized separately. Most of pharmacologic agents act through inhibition of nitric oxide synthase and reduction in nitric oxide production, inactivation of endothelin-1, and treatment of bacterial translocation and pulmonary angiogenesis. **Conclusion.** Several drugs have been applied for the treatment of HPS with conflicting results. However, no large randomized trial has been conducted probably due to low number of patients. Multicentered clinical trials are necessary to investigate these drugs.

1. Introduction

Hepatopulmonary syndrome (HPS) is the development of pulmonary dysfunction characterized by defective arterial oxygenation in the context of liver disease. A triad of liver disease, pulmonary vascular dilation, and arterial hypoxemia secondary to pulmonary gas exchanges abnormalities are necessary for diagnosis of HPS [1]. Although it is more common in patients with liver cirrhosis, HPS can also occur in patients with acute liver failure like fulminant hepatitis A and ischemic hepatitis [2, 3]. The reports of HPS prevalence have varied from 4% to 33% mainly due to lack of diagnostic criteria and using different cut-offs in different studies [4–7].

Nowadays, liver transplantation is the only effective therapy for HPS. By lengthening transplant waiting lists, patients with liver cirrhosis succumb to complications of liver cirrhosis including HPS. Therefore, medical therapy either as a bridge to transplant or as a final treatment for HPS should

be considered in future studies. Herein, we have reviewed current pharmacological therapies against HPS.

2. Methods

2.1. Search Strategy. The study was conducted using preferred reporting items for systematic review and meta-analyses PRISMA guidelines, flow diagram, and checklist [8]. A computerized English language literature search of PUBMED was performed in January 2013. Studies that had been published in any time were included in review. Both human and animal studies were included. After a preliminary search in MeSH database, we used the terms “hepatopulmonary syndrome” and “treatment,” “medical treatment,” and “drug treatment as key words in titles and/or abstracts.

2.2. Eligibility and Critical Appraisal of the Studies. We reviewed all studies and carefully appraised them to be included

in the study. All descriptive/analytical cross-sectional studies, case-control studies, clinical trials, experimental studies, and relevant case reports with proper methods for assessment of HPS were included. Editorials, hypotheses, studies on cell lines, abstracts from conferences, or unpublished reports were excluded. Studies reporting treatment of HPS with liver transplantation or other interventional nonmedical therapies were excluded (Figure 1). Two reviewers abstracted data from full texts of the relevant articles.

3. Results

In electronic search, total of 75 studies out of 451 studies were reviewed and appraised for relevance and validity. After exclusion of studies with other determinants, studies that are not representative of our aims, editorials, finally 29 studies were included, and the results were categorized in subsections.

3.1. Pathophysiology. Pulmonary gas exchange abnormalities in HPS result from three pathological mechanisms: ventilation-perfusion mismatch, right to left shunting, and diffusion limitation [1]. All of these three mechanisms are consequences of a central abnormality which is dilatation in pulmonary precapillary and capillary vessels as well as increased numbers of these dilated vessels [1]. Main underlying mediators and pathophysiological basis for these changes that are potential targets for pharmacological therapies are discussed (Figure 2).

3.1.1. Nitric Oxide. Nitric oxide (NO) is a product of the action of nitric oxide synthase (NOS) on L-arginine and is potent vasodilator acting by relaxation of vascular smooth muscle cell [9]. The crucial role of NO pathway has been suggested in the development of HPS in experimental and human studies. Cirrhotic patients with HPS have higher levels of exhaled NO compared to cirrhotic patients without HPS [10]. NOS isoforms are upregulated in rat model of cirrhosis with HPS [11]. Furthermore, alveolar macrophage NOS is upregulated by increased levels of tumor necrosis factor- α (TNF- α) in cirrhosis and HPS [12]. Increased levels of (TNF- α) in cirrhosis are secondary to endotoxemia as a result of bacterial translocation in these patients [13].

3.1.2. Pulmonary Angiogenesis. Cirrhosis and HPS are accompanied by increased pulmonary capillary proliferation as observed in autopsied patients with HPS [14]. Bacterial translocation and subsequent increase in (TNF- α) results in recruitment of pulmonary intravascular monocytes and activation of vascular endothelial growth factor-dependent pathways [15]. These changes are contributing events in increasing pulmonary angiogenesis; however, a genetic predisposition has been suggested in this process [16].

3.1.3. Endothelin-1. Plasma level of endothelin-1 (ET-1) is increased in cirrhosis and is substantially increased in patients with HPS [17, 18]. Pulmonary endothelin B receptors (ET_B) are highly expressed in patients with HPS,

FIGURE 1: Flow diagram of review.

FIGURE 2: Main pathophysiological mechanisms and available drugs against hepatopulmonary syndrome. PTX: pentoxifylline, MB: methylene blue, MMF: mycophenolate mofetil, and CAPE: caffeic acid phenethyl ester.

and activation of ET_B results in NO-induced vasodilatation [19]. Therefore, ET-1 is another target for future studies to find a treatment for HPS.

Current drugs and main underlying mechanism are discussed separately (Table 1).

3.2. Pentoxifylline. Pentoxifylline (PTX) is a nonspecific phosphodiesterase inhibitor that nonspecifically inhibits tumor necrosis factor- α (TNF- α) [20]. It has also other anti-inflammatory properties including inhibition of monocyte chemoattractant protein-1 (MCP-1), macrophage inhibitory protein-1 (MIP-1), interleukin-6 and interleukin-8, decreased expression of adhesion molecules, and decreased activation and proliferation of neutrophils [21–24].

PTX has been widely used in peripheral vascular diseases like intermittent claudication [25], in vascular dementia [26], and with corticosteroid in alcoholic hepatitis [27]. PTX is among few drugs that have been used in experimental and human studies for treatment of HPS. This application

TABLE 1: Summary of human studies using pharmacologic agents for the treatment of hepatopulmonary syndrome.

Study	Patients	Age (year)	Male/female	Drug	Dose	Duration	Outcome
Gupta et al. [32]	9 patients with cirrhosis	40	5/4	PTX	400 mg 3 times/day	3 months	(i) Improvement of clinical symptoms (ii) Improvement of PaO ₂ (iii) Decreased TNF- α
Kianifar et al. [33]	10 pediatric patient with cirrhosis	9.2 $\pm$ 5	6/4	PTX	20 mg/kg/day	3 months	(i) Increase in PaO ₂ and A-a PaO ₂ (ii) Improvement of O ₂ saturation (iii) No Improvement in Clinical symptoms
Tanikella et al. [34]	9 patients with cirrhosis	55 $\pm$ 10	3/6	PTX	(i) 400 mg/day (ii) 400 mg twice/day (iii) 400 mg 3 times/day	(i) 7 days (ii) 7 days (iii) 42 days	(i) No significant change in PaO ₂ (ii) No significant change in A-a PaO ₂ (iii) No significant change in TNF- α
Rolla et al. [40]	1 patient with alcoholic cirrhosis	45	Female	MB	3 mg/kg intravenous	One bolus dose	(i) Improvement in PaO ₂ (ii) Improvement in O ₂ saturation
Schenk et al. [41]	7 patients with liver cirrhosis	52	5/2	MB	3 mg/kg intravenous	One bolus dose in 15 minutes	(i) Improvement of PaO ₂ (ii) Improvement of A-a PaO ₂ (iii) Increased mean pulmonary arterial pressure and pulmonary vascular resistance
Jouineaux et al. [42]	1 patient with alcoholic cirrhosis	61	Male	MB	3 mg/kg intravenous	One bolus dose	(i) Increased mean pulmonary arterial pressure (ii) No change in shunt fraction
Roma et al. [43]	1 liver transplant patient for AIH	15	Female	MB	3 mg/kg intravenous	One bolus dose in 15 minutes	(i) Increased O ₂ saturation (ii) As abridge for weaning of from ventilator
Añel and Sheagren [52]	1 patient with cirrhosis	44	Male	Norfloxacin	400 mg 2 times/day	4 weeks	(i) Increased O ₂ saturation (ii) Resolution of platypnea and orthodeoxia
Gupta et al. [53]	11 patients with cirrhosis	60 $\pm$ 9	8/1	Norfloxacin	400 mg 4 times/day	1 month	(i) No improvement in HPS
Caldwell et al. [54]	1 patient with cirrhosis	60	Female	Garlic	4 teaspoons 4 times/day	4 months	(i) Improvement of cyanosis (ii) Increased PaO ₂
Abrams and Fallon [55]	15 patients with cirrhosis	NA	7/8	Garlic	2 Capsule (500 mg) 2 times/day	6 months	(i) Increased PaO ₂ (ii) Decreased A-a PaO ₂ (iii) Decreased dyspnea on exertion
Sani et al. [56]	15 pediatric patients with cirrhosis	9.4 $\pm$ 3.9	10/5	Garlic	0.5–2 g/1.73 m ² per day	4 weeks	(i) Increased PaO ₂ (ii) Improvement of dyspnea

TABLE 1: Continued.

Study	Patients	Age (year)	Male/female	Drug	Dose	Duration	Outcome
De et al. [57]	41 cirrhotic patients, 21 patients received garlic, 20 received placebo	37.6 ± 13.06	17/4	Garlic	1 capsule (250 mg) 2 times/day	18 months	(i) Increased PaO ₂ (ii) Decreased A-a PaO ₂ (iii) Reversal of HPS in 14 from 21 patients
Maniscalco et al. [63]	1 patient with cryptogenic cirrhosis	31	Male	L-NAME	8 mg/kg in normal saline	Intravenously over 5 minutes	(i) Decreased NO production (ii) No improvement in arterial oxygenation (iii) No improvement in orthodeoxia
Gómez et al. [64]	10 cirrhotic patients with HPS	60 ± 7	7/3	L-NAME	Single dose, 162.0 mg dissolved in 4.0 mL 0.9% saline	Nebulized over 12 minutes	(i) Decreased exhaled NO (ii) Increased systemic vascular resistance (iii) No change in ventilation/perfusion mismatch, intrapulmonary shunting, nor arterial oxygenation
Moreira Silva et al. [75]	1 patient with autoimmune lymphoproliferative syndrome	13	Male	MMFL	500 mg twice/day	9 months	(i) Improvement of cyanosis, clubbing, and spider nevi (ii) Normalization of PaO ₂ (iii) No need for supplemental oxygen (iv) Improvement of intrapulmonary shunt
Yilmaz et al. [76]	1 patient with noncirrhotic portal hypertension	18	Male	Paroxetine	20 mg/day	6 months	(i) No significant improvement
Krug et al. [82]	1 patient with alcoholic cirrhosis	46	Female	Inhaled iloprost	30 µg/day nebulized	2 months	(i) Decreased subjective dyspnea (ii) Increased exercise tolerance (iii) Increase in PaO ₂
Krowka et al. [84]	22 patients with cirrhosis or chronic active hepatitis (8 patients received the drug)	49	12/10	Somatostatin analogue	150 µg every 8 hours subcutaneously	4 days	(i) No improvement in subjective dyspnea (ii) No improvement in arterial oxygenation at the end of study

HPS: hepatopulmonary syndrome, PTX: pentoxifylline, MB: methylene blue, PaO₂: arterial oxygen pressure, and A-a PaO₂: alveolar-arterial oxygen gradient.
MMFL: mycophenolate mofetil, L-NAME: N^G-nitro-L-arginine methyl ester, and NO: nitric oxide.

is mainly based on its 2 characteristics of PTX: its inhibitory effect on iNOS leading to subsequent decrease in NO production and the newly found PTX effect on downregulation of angiogenesis [28]. In an animal study, PTX was used prophylactically in rat model of liver cirrhosis induced by common bile duct ligation [29]. In this study rats, treated with PTX were protected from development of HPS. Blood concentration of TNF- α and iNOS expression were significantly reduced in PTX-treated rats. Another experimental study demonstrated that PTX administration for 2 weeks after CBD ligation in rats improved HPS and pulmonary gas exchange [30]. Rats treated with PTX have decreased NOS activity, down regulation of pulmonary endothelial endothelin-B (ET-B) receptor, reversal of pulmonary Akt activation, and partially reversal of TNF- α . Zhang et al. showed the crucial role of angiogenesis and increased lung microvessels in pathogenesis of HPS via activation of vascular endothelial growth factor (VEGF)-A pathway. PTX-reduced number of pulmonary micro vessels reduced monocyte infiltration and down regulation of VEGF-A [31].

Despite these beneficial effects of PTX in animal models, few human studies had conflicting results. A nonrandomized clinical trial of 3 months administration of PTX (400 mg 3 times daily) for 9 cirrhotic patients with HPS showed beneficial effect of this medication in improvement of dyspnea, palmar erythema, and cyanosis. PTX therapy was also associated with marked improvement in arterial O₂ pressure, exercise-induced change in oxygen, and decreased median levels of TNF- α without significant adverse reaction [32]. These findings were confirmed in another study that revealed the effect of 3 months of PTX therapy (20 mg/kg per day) in increasing arterial oxygen pressure, oxygen saturation, and arterial-alveolar oxygen gradient in pediatric patients with liver cirrhosis although PTX failed to improve clinical symptoms of dyspnea and cyanosis [33]. After discontinuation of PTX, arterial oxygen pressure decreased, and arterial-alveolar oxygen gradient increased significantly. However, Tanikella et al. could not find any improvement after PTX therapy (400 mg once daily by mouth for 7 days followed by 400 mg twice daily for 7 days and then 400 mg thrice daily for 42 days) in cirrhotic patients with HPS. Blood level of TNF- α was not altered significantly before and after treatment with PTX. They discussed that their results are probably due to poor tolerance of PTX and appearance of its side effects in patients that mandated lowering dose of drug [34]. Despite these relatively favorable results, there is no randomized, placebo, controlled trial regarding the use of PTX in patients with HPS.

3.3. Methylene Blue. Dimethylamino phenazathionium chloride trihydrate, methylene blue (MB), has been used in medicine as a contrast agent for diagnostic purposes like chromoendoscopy [35], for the treatment of methemoglobinemia [36] and recently for septic shock due to its inhibitory effect on NO-induced vasodilatation [37]. The vasoconstrictor effect of MB results from its inhibitory influence on activation of soluble guanylate cyclase by NO [38]. An animal study showed that MB is effective in improvement

of arterial oxygen pressure and alveolar-arterial gradient in CBD-ligated rats. This study showed that MB therapy reduced proliferation of alveolar capillary vessels and angiogenesis in pathology [39]. The first report of successful clinical application of MB for treatment of HPS backed to 1994 in a patient with alcoholic cirrhosis [40]. The patient's partial pressure of oxygen and oxygen saturation was significantly improved after a bolus of intravenous (i.v) administration of MB (3 mg per kilogram). Afterwards, Schenk and coworkers showed beneficial effect of i.v administration of MB (3 mg per kilogram) in 7 patients with HPS [41]. They have also reported effects of MB in decreasing cardiac output, pulmonary artery pressure and increasing systemic vascular resistance, and pulmonary vascular resistance. Improvement of HPS after i.v MB infusion with the above mentioned dose has been reported in a patient with alcoholic cirrhosis [42]. Interestingly, Roma et al. reported use of MB in a patient with liver cirrhosis and HPS after liver transplantation for the improvement of pulmonary gas exchange and weaning from mechanical ventilation. They concluded that MB can be used to improve hypoxemia and reduce postliver transplant complications [43]. The useful effect of MB in improvement of HPS in these studies can be attributed to its inhibitory effect on NOS activity and subsequent reduction of NO which is a potent vasodilator of pulmonary vasculature. Furthermore, MB administration has been shown to ameliorate angiogenesis, another main mechanism in HPS, possibly by acting through inhibition of VEGF and platelet-derived-growth-factor-(PDGF-) dependent pathways [39, 44, 45]. Like PTX, no randomized placebo trial has been conducted to investigate the application of MB in patients with HPS.

3.4. Norfloxacin. Bacterial translocation, dissemination of gut bacteria through the body, is a recognized phenomenon in liver cirrhosis that is taking place due to disruption of gut mucosal barriers and impaired host defense [46]. Bacterial translocation may affect the lung and have potential influence on development of HPS. In the setting of liver cirrhosis, the bacterial endotoxins that are normally filtered by Kupffer cells in liver can enter the lung [47]. Activated macrophages of pulmonary system try to compensate the clearing activity of liver cells and begin to secrete several cytokines and NO [48]. In fact NO synthesis is increased in pulmonary vasculature of cirrhotic rats secondary to overexpression of NOS in pulmonary macrophages [49]. These facts lead to this notion that treatment of bacterial overgrowth in the gut for the prevention of bacterial translocation may be helpful to control HPS via suppression of NO synthesis. Norfloxacin, an active quinolone antibiotic against gram negative bacteria, has been a candidate because of its potential to prevent bacterial translocation [50]. An animal study showed the efficacy of norfloxacin in decreasing bacterial translocation to lung, decreasing pulmonary macrophages, and reducing activity of NOS in CBD-ligated cirrhotic rats [51]. They conclude that norfloxacin therapy can ameliorate severity of HPS and can be considered in human studies. Añel and Sheagren reported improvement of a patient with HPS in the context of liver cirrhosis after intake of oral norfloxacin (400 mg 2 times

per day) [52]. A pilot randomized crossover clinical trial of norfloxacin (400 mg four times daily for 1 month) failed to show any improvement in HPS in patients with liver cirrhosis. They discussed that the pathophysiological changes in HPS are probably preventable (as in animal models) but may not be reversible in human studies [53]. Despite the negative results of this trial, antibacterial treatment with norfloxacin can be considered in larger multicentre randomized trials for treatment of HPS.

3.5. Garlic. Garlic (*Allium sativum*) is an ancient herbal remedy which is also used frequently in daily food all over the world from centuries ago. Irrespective of the underlying mechanism, garlic has been used in patients with HPS. The first report of garlic use in HPS returned to 1992 in a 60-year-old cirrhotic woman with significant improvement of her cyanosis, oxygen saturation after being treated with 4 teaspoons of garlic powder once or twice a day [54]. Improvement of HPS with garlic capsule (once daily for 6 months) was also observed in a pilot trial among 15 patients with HPS. After completing course of treatment significant improvement was observed in arterial oxygenation and subjective decrease in clinical symptoms [55]. Oral garlic capsule was also used in pediatric patients with HPS for 5 months with subsequent improvement of arterial oxygen pressure and oxygen saturation [56]. Another recently published randomized clinical trial confirmed beneficial effects of garlic capsule in improvement of HPS [57]. In this study, 18 months of oral garlic capsule therapy in patients with cirrhosis resulted in improvement of arterial oxygen pressure, Alveolar-arterial oxygen gradient and reversal of HPS in two thirds of patients.

Despite these favorable results, the underlying mechanisms for efficacy of garlic therapy in HPS have not been elucidated yet. Paradoxically, garlic has been reported to cause an increase in NO synthesis [58] and induce pulmonary vasodilation and therefore is expected to worsen HPS [59]. Abrams and Fallon explained that garlic therapy leads to redistribution of pulmonary blood flow to mid and apical portions of lungs as a result of uniform vasodilation [55]. This results in an improvement in ventilation/perfusion ratio and HPS. Another probable mechanism is the antiangiogenesis properties of garlic which has been shown in some studies [60, 61].

3.6. Inhibition of NO Synthesis. As discussed in previous sections, increased NO synthesis in pulmonary vasculature has a major role in pathogenesis of HPS. Therefore, targeting NO pathway is supposed to be a therapeutic option in treatment of HPS. In an experimental study, oral administration of an inhibitor of NOS activity, N^G-nitro-L-arginine methyl ester (L-NAME), was shown to decrease NO synthesis and prevent HPS in a rat model of cirrhosis [62]. However, inhaled (L-NAME) was not able to ameliorate HPS in cirrhotic patients despite the decreased NO synthesis [63]. A human study of 10 patients with liver cirrhosis and HPS failed to demonstrate any improvement in arterial deoxygenation, ventilation-perfusion mismatching and intrapulmonary shunt [64].

On the other hand, increased NO synthesis seems to improve HPS secondary to ischemic reperfusion injury in rats [65]. Inhaled NO was reported to improve HPS during and after liver transplantation [66].

3.7. Quercetin. Flavonoids are frequently present in fruits, vegetables, tea and wine and act as antioxidant agents in human body [67]. Quercetin (3,5,7,3'-4'-flavone) is the major flavonoids in human diet with several beneficial effects on human health [68]. Nuclear factor- κ B (NF- κ B) pathway is one of the major signaling pathway involved in HPS. Activation of this pathway results in migration of NF- κ B to nucleus and subsequent changes in expression of NOS and heme oxygenase-1 (HO-1) [69]. Quercetin has been applied in CBD-ligated cirrhotic rats and has been reported to be effective in decreasing oxidative stress, nuclear translocation of NF- κ B, expression of NOS, HO-1, and endothelin B (ET-B) receptor and improvement of HPS [70]. Quercetin was also capable of reducing expression of ET-1 which can enhance NOS and supposed to be a major role in HPS. Another animal study confirmed protective effect of quercetin in the development of HPS by inhibition of DNA damage and induction of superoxide dismutase activity [71]. There is no human report of using quercetin in patients with HPS.

3.8. Mycophenolate Mofetil (MMF). MMF is an immunosuppressive agent which is commonly used in transplant medicine and other immune-mediated diseases. MMF inhibits NO production by blocking TNF- α and interferon- γ (IFN- γ) in endothelial cells [72]. Furthermore, MMF acts against HPS by reducing ET-1 that is another way to inhibit NOS activity [73]. It should be noted that MMF may inhibit angiogenesis by its potent inhibitory effect on endothelial cells and fibroblast proliferation [74]. There is only one report of improvement of HPS after using MMF (500 mg twice daily) in the literature [75]. It is noteworthy that MMF was capable of significant improvement of clinical signs including clubbing, cyanosis, and spider nevi. MMF can be the subject for future studies in this area of research.

3.9. Paroxetine. Yilmaz et al. reported a patient with idiopathic pulmonary hypertension complicated by HPS that was treated by paroxetine (20 mg daily) for 6 months [76] without any improvement in outcomes.

3.10. Sorafenib. Sorafenib is a multikinase inhibitor targeting several signaling pathways including Raf/mitogen-activated protein kinase/extracellular signal-regulated kinase (Raf/MEK/ERK) signaling pathway and tyrosine kinases vascular endothelial growth factor (VEGF), receptor 2 (VEGFR-2), VEGFR-3, and platelet-derived growth factor receptor (PDGF-R) pathways [77]. It is currently used as an antiangiogenesis agent in patients with hepatocellular carcinoma and some other solid tumors. Sorafenib has been successfully used in rat model of cirrhosis for prevention of HPS and has been shown to reduce alveolar-arterial oxygen gradient, and intrapulmonary shunting. It was also accompanied with reduction in intrapulmonary angiogenesis through reduction

in plasma VEGF level and attenuation of VEGF mRNA and VEGF receptor-2 expression [78]. A human study confirmed the beneficial effects of sorafenib in the reduction of intrapulmonary shunt in HPS secondary to advanced hepatocellular carcinoma [79].

3.11. Iloprost. Iloprost is a synthetic analogue of prostacyclin (PGI_2) which is frequently used intravenously for the treatment of pulmonary hypertension [80]. PGI_2 is synthesized and released from pulmonary endothelial cells and increased intracellular concentration of cyclic adenosine monophosphate (cAMP) causing vasodilatation of pulmonary and systemic circulation by relaxation of smooth muscles and prevention of platelet aggregation [81]. Inhaled iloprost is an alternative form of PGI_2 which is approved for the treatment of pulmonary hypertension. Inhaled iloprost has been applied for the treatment of HPS in posttransplant period and was outlined to be effective in the improvement of clinical symptoms and hypoxemia [82].

3.12. N-Acetyl Cysteine. N-acetyl cysteine, an inhibitor of reactive oxygen species, has been shown to attenuate HPS in rat models of cirrhosis [83]. Improvement of arterial blood gases and reversal of pulmonary vasodilatation in pathology was observed in the study. In this study, intraperitoneal administration of N-acetyl cysteine to CBD-ligated rats was accompanied with inhibition of nitrate production and DNA damage compared to the control group. Furthermore, superoxide dismutase activity, as a marker of oxidative stress, was reduced in rats after CBD ligation, but in rats treated with N-acetyl cysteine, the superoxide dismutase activity remained in normal range.

3.13. Somatostatin Analogue. A retrospective analysis of 22 patients with HPS in the context of liver cirrhosis failed to demonstrate any improvement in arterial oxygenation and clinical symptoms after subcutaneous administration of a somatostatin analogue [84].

3.14. Caffeic Acid Phenethyl Ester (CAPE). CAPE is an antioxidant, anti-inflammatory agent which has shown to reduce NO synthesis and inhibit pulmonary fibrosis [85, 86]. Tekin et al. showed beneficial effect of intraperitoneal CAPE on the reduction of plasma NO and improvement of HPS and mortality in rats [87].

4. Conclusion

Despite promising outcomes from treatment of HPS with several drugs, results can not be generalized to all patients due to the lack of randomized trials with proper study population. PTX, MB, and MMF especially had promising results in these studies. Targeting main pathophysiological basis for treatment of HPS should be considered for future studies. Large randomized placebo controlled trials are necessary for investigation of the efficacy of these agents in the improvement of survivals both before and after transplantation.

Authors' Contribution

All authors have contributed to the review properly and have approved the final version and authorship list. Dr. Ahad Eshraghian is the guarantor of the current paper.

References

- [1] R. Rodríguez-Roisin and M. J. Krowka, "Hepatopulmonary syndrome—a liver-induced lung vascular disorder," *The New England Journal of Medicine*, vol. 358, no. 22, pp. 2378–2387, 2008.
- [2] A. Regev, M. Yeshurun, M. Rodriguez et al., "Transient hepatopulmonary syndrome in a patient with acute hepatitis A," *Journal of Viral Hepatitis*, vol. 8, no. 1, pp. 83–86, 2001.
- [3] V. Fuhrmann, C. Madl, C. Mueller et al., "Hepatopulmonary syndrome in patients with hypoxic hepatitis," *Gastroenterology*, vol. 131, no. 1, pp. 69–75, 2006.
- [4] J. K. Stoller, P. A. Lange, M. K. Westveer, W. D. Carey, D. Vogt, and J. M. Henderson, "Prevalence and reversibility of the hepatopulmonary syndrome after liver transplantation—The Cleveland Clinic experience," *Western Journal of Medicine*, vol. 163, no. 2, pp. 133–138, 1995.
- [5] G. P. Martínez, J. A. Barberà, J. Visa et al., "Hepatopulmonary syndrome in candidates for liver transplantation," *Journal of Hepatology*, vol. 34, no. 5, pp. 651–657, 2001.
- [6] M. B. Fallon, M. J. Krowka, R. S. Brown et al., "Impact of hepatopulmonary syndrome on quality of life and survival in liver transplant candidates," *Gastroenterology*, vol. 135, no. 4, pp. 1168–1175, 2008.
- [7] S. M. Dehghani, S. Aleyasin, N. Honar et al., "Pulmonary evaluation in pediatric liver transplant candidates," *Indian Journal of Pediatrics*, vol. 78, no. 2, pp. 171–175, 2011.
- [8] A. Liberati, D. G. Altman, J. Tetzlaff et al., "The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration," *PLoS Medicine*, vol. 6, no. 7, Article ID e1000100, 2009.
- [9] J.-Z. Tan, G. Kaley, and G. H. Gurtner, "Nitric oxide and prostaglandins mediate vasodilation to 5,6-EET in rabbit lung," *Advances in Experimental Medicine and Biology*, vol. 407, pp. 561–566, 1996.
- [10] G. Rolla, L. Brussino, P. Colagrande et al., "Exhaled nitric oxide and oxygenation abnormalities in hepatic cirrhosis," *Hepatology*, vol. 26, no. 4, pp. 842–847, 1997.
- [11] H. Nunes, D. Lebrec, M. Mazmanian et al., "Role of nitric oxide in hepatopulmonary syndrome in cirrhotic rats," *American Journal of Respiratory and Critical Care Medicine*, vol. 164, no. 5, pp. 879–885, 2001.
- [12] L. Liu, N. Liu, Z. Zhao et al., "TNF-alpha neutralization improves experimental hepatopulmonary syndrome in rats," *Liver International*, vol. 32, pp. 1018–1026, 2012.
- [13] I. Cirera, T. Martin Bauer, M. Navasa et al., "Bacterial translocation of enteric organisms in patients with cirrhosis," *Journal of Hepatology*, vol. 34, pp. 32–37, 2001.
- [14] P. Berthelot, J. G. Walker, S. Sherlock, and L. Reid, "Arterial changes in the lungs in cirrhosis of the liver—lung spider nevi," *The New England Journal of Medicine*, vol. 274, no. 6, pp. 291–298, 1966.
- [15] J. Zhang, W. Yang, B. Luo, B. Hu, A. Maheshwari, and M. B. Fallon, "The role of CX(3)CL1/CX(3)CR1 in pulmonary

- angiogenesis and intravascular monocyte accumulation in rat experimental hepatopulmonary syndrome," *Journal of Hepatology*, vol. 57, pp. 752–758, 2012.
- [16] K. E. Roberts, S. M. Kawut, M. J. Krowka et al., "Genetic risk factors for hepatopulmonary syndrome in patients with advanced liver disease," *Gastroenterology*, vol. 139, no. 1, pp. 130.e24–139.e24, 2010.
 - [17] B. Luo, G. A. Abrams, and M. B. Fallon, "Endothelin-1 in the rat bile duct ligation model of hepatopulmonary syndrome: correlation with pulmonary dysfunction," *Journal of Hepatology*, vol. 29, no. 4, pp. 571–578, 1998.
 - [18] D. G. Koch, G. Bogatkevich, V. Ramshesh, J. J. Lemasters, R. Uflacker, and A. Reuben, "Elevated levels of endothelin-1 in hepatic venous blood are associated with intrapulmonary vasodilatation in humans," *Digestive Diseases and Sciences*, vol. 57, no. 2, pp. 516–523, 2012.
 - [19] B. Luo, L. Liu, L. Tang et al., "Increased pulmonary vascular endothelin B receptor expression and responsiveness to endothelin-1 in cirrhotic and portal hypertensive rats: a potential mechanism in experimental hepatopulmonary syndrome," *Journal of Hepatology*, vol. 38, no. 5, pp. 556–563, 2003.
 - [20] P. Zabel, F. U. Schade, and M. Schlaak, "Inhibition of endogenous TNF formation by pentoxifylline," *Immunobiology*, vol. 187, no. 3–5, pp. 447–463, 1993.
 - [21] Y.-M. Chen, S.-L. Lin, W.-C. Chiang, K.-D. Wu, and T.-J. Tsai, "Pentoxifylline ameliorates proteinuria through suppression of renal monocyte chemoattractant protein-1 in patients with proteinuric primary glomerular diseases," *Kidney International*, vol. 69, no. 8, pp. 1410–1415, 2006.
 - [22] N. Poulakis, G. Androutsos, D. Kazi et al., "The differential effect of pentoxifylline on cytokine production by alveolar macrophages and its clinical implications," *Respiratory Medicine*, vol. 93, no. 1, pp. 52–57, 1999.
 - [23] P. Neuner, G. Klosner, M. Pourmojib, R. Knobler, and T. Schwarz, "Pentoxifylline in vivo and in vitro down-regulates the expression of the intercellular adhesion molecule-1 in monocytes," *Immunology*, vol. 90, no. 3, pp. 435–439, 1997.
 - [24] K. Toda, N. Kumagai, F. Kaneko et al., "Pentoxifylline prevents pig serum-induced rat liver fibrosis by inhibiting interleukin-6 production," *Journal of Gastroenterology and Hepatology*, vol. 24, no. 5, pp. 860–865, 2009.
 - [25] K. Salhiyyah, E. Senanayake, M. Abdel-Hadi, A. Booth, and J. A. Michaels, "Pentoxifylline for intermittent claudication," *Cochrane Database of Systematic Reviews*, vol. 1, Article ID CD005262, 2012.
 - [26] M. C. Sha and C. M. Callahan, "The efficacy of pentoxifylline in the treatment of vascular dementia: a systematic review," *Alzheimer Disease and Associated Disorders*, vol. 17, no. 1, pp. 46–54, 2003.
 - [27] K. Whitfield, A. Rambaldi, J. Wetterslev, and C. Gluud, "Pentoxifylline for alcoholic hepatitis," *Cochrane Database of Systematic Reviews*, no. 4, Article ID CD007339, 2009.
 - [28] V. Trajković, V. Badovinac, D. Popadić, O. Hadžić, and M. M. Stojković, "Cell-specific effects of pentoxifylline on nitric oxide production and inducible nitric oxide synthase mRNA expression," *Immunology*, vol. 92, no. 3, pp. 402–406, 1997.
 - [29] B. Sztrymf, A. Rabiller, H. Nunes et al., "Prevention of hepatopulmonary syndrome and hyperdynamic state by pentoxifylline in cirrhotic rats," *European Respiratory Journal*, vol. 23, no. 5, pp. 752–758, 2004.
 - [30] J. Zhang, Y. Ling, L. Tang et al., "Pentoxifylline attenuation of experimental hepatopulmonary syndrome," *Journal of Applied Physiology*, vol. 102, no. 3, pp. 949–955, 2007.
 - [31] J. Zhang, B. Luo, L. Tang et al., "Pulmonary angiogenesis in a rat model of hepatopulmonary syndrome," *Gastroenterology*, vol. 136, no. 3, pp. 1070–1080, 2009.
 - [32] L. B. Gupta, A. Kumar, A. K. Jaiswal et al., "Pentoxifylline therapy for hepatopulmonary syndrome: A Pilot Study," *Archives of Internal Medicine*, vol. 168, no. 16, pp. 1820–1823, 2008.
 - [33] H. R. Kianifar, M. Khalesi, and E. Mahmoodi, "Afzal Aghaei M. Pentoxifylline in hepatopulmonary syndrome," *World Journal of Gastroenterology*, vol. 18, no. 35, pp. 4912–4916, 2012.
 - [34] R. Tanikella, G. M. Philips, D. K. Faulk, S. M. Kawut, and M. B. Fallon, "Pilot study of pentoxifylline in hepatopulmonary syndrome," *Liver Transplantation*, vol. 14, no. 8, pp. 1199–1203, 2008.
 - [35] S. A. Taghavi, M. E. Membari, A. Eshraghian, S. M. Dehghani, L. Hamidpour, and F. Khademalhosseini, "Comparison of chromoendoscopy and conventional endoscopy in the detection of premalignant gastric lesions," *Canadian Journal of Gastroenterology*, vol. 23, no. 2, pp. 105–108, 2009.
 - [36] S. M. Bradberry, "Occupational methaemoglobinaemia: mechanisms of production, features, diagnosis and management including the use of methylene blue," *Toxicological Reviews*, vol. 22, no. 1, pp. 13–27, 2003.
 - [37] C. A. Paciullo, D. M. Horner, K. W. Hatton, and J. D. Flynn, "Methylene blue for the treatment of septic shock," *Pharmacotherapy*, vol. 30, no. 7, pp. 702–715, 2010.
 - [38] N. Marczin, U. S. Ryan, and J. D. Catravas, "Methylene blue inhibits nitrovasodilator- and endothelium-derived relaxing factor-induced cyclic GMP accumulation in cultured pulmonary arterial smooth muscle cells via generation of superoxide anion," *Journal of Pharmacology and Experimental Therapeutics*, vol. 263, no. 1, pp. 170–179, 1992.
 - [39] A. Miyamoto, Y. Katsuta, X.-J. Zhang et al., "Effect of chronic methylene blue administration on hypoxemia in rats with common bile duct ligation," *Hepatology Research*, vol. 40, no. 6, pp. 622–632, 2010.
 - [40] G. Rolla, C. Bucca, and L. Brussino, "Methylene blue in the hepatopulmonary syndrome," *The New England Journal of Medicine*, vol. 331, no. 16, p. 1098, 1994.
 - [41] P. Schenk, C. Madl, S. Rezaie-Majd, S. Lehr, and C. Muller, "Methylene blue improves the hepatopulmonary syndrome," *Annals of Internal Medicine*, vol. 133, no. 9, pp. 701–706, 2000.
 - [42] V. Jounieaux, O. Leleu, and I. Mayeux, "Cardiopulmonary effects of nitric oxide inhalation and methylene blue injection in hepatopulmonary syndrome," *Intensive Care Medicine*, vol. 27, no. 6, pp. 1103–1104, 2001.
 - [43] J. Roma, E. Balbi, L. Pacheco-Moreira et al., "Methylene blue used as a bridge to liver transplantation postoperative recovery: a case report," *Transplantation Proceedings*, vol. 42, no. 2, pp. 601–604, 2010.
 - [44] A. Boztosun, A. Piçnak, M. I. Kosar, S. Gulturk, and A. Cetin, "Effects of methylene blue, pentoxifylline and enoxaparin on postoperative adhesion formation and markers of angiogenesis in a rat uterine horn model," *Clinical & Experimental Obstetrics & Gynecology*, vol. 39, no. 1, pp. 89–95, 2012.
 - [45] N. Zacharakis, P. Tone, C. S. Flordellis, M. E. Maragoudakis, and N. E. Tsopanoglou, "Methylene blue inhibits angiogenesis in chick chorioallantoic membrane through a nitric oxide-independent mechanism," *Journal of Cellular and Molecular Medicine*, vol. 10, no. 2, pp. 493–498, 2006.

- [46] R. Wiest, S. Das, G. Cadelina, G. Garcia-Tsao, S. Milstien, and R. J. Groszmann, "Bacterial translocation in cirrhotic rats stimulates eNOS-derived NO production and impairs mesenteric vascular contractility," *Journal of Clinical Investigation*, vol. 104, no. 9, pp. 1223–1233, 1999.
- [47] E. Miot-Noirault, L. Faure, Y. Guichard, J. Montharu, and A. Le Pape, "Scintigraphic in vivo assessment of the development of pulmonary intravascular macrophages in liver disease: experimental study in rats with biliary cirrhosis," *Chest*, vol. 120, no. 3, pp. 941–947, 2001.
- [48] R. J. Panos and S. K. Baker, "Mediators, cytokines, and growth factors in liver-lung interactions," *Clinics in Chest Medicine*, vol. 17, no. 1, pp. 151–170, 1996.
- [49] H. Nunes, D. Lebrec, M. Mazmanian et al., "Role of nitric oxide in hepatopulmonary syndrome in cirrhotic rats," *American Journal of Respiratory and Critical Care Medicine*, vol. 164, no. 5, pp. 879–885, 2001.
- [50] P. Gines, A. Rimola, R. Planas et al., "Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: results of a double-blind, placebo-controlled trial," *Hepatology*, vol. 12, no. 4 I, pp. 716–724, 1990.
- [51] A. Rabiller, H. Nunes, D. Lebrec et al., "Prevention of Gram-negative translocation reduces the severity of hepatopulmonary syndrome," *American Journal of Respiratory and Critical Care Medicine*, vol. 166, no. 4, pp. 514–517, 2002.
- [52] R. M. Añel and J. N. Sheagren, "Novel presentation and approach to management of hepatopulmonary syndrome with use of antimicrobial agents," *Clinical Infectious Diseases*, vol. 32, no. 10, pp. E131–E136, 2001.
- [53] S. Gupta, M. E. Faughnan, L. Lilly, S. Hutchison, R. Fowler, and A. M. Bayoumi, "Norfloxacin therapy for hepatopulmonary syndrome: a pilot randomized controlled trial," *Clinical Gastroenterology and Hepatology*, vol. 8, no. 12, pp. 1095–1098, 2010.
- [54] S. H. Caldwell, L. J. Jeffers, O. S. Narula, E. A. Lang, K. R. Reddy, and E. R. Schiff, "Ancient remedies revisited: does *Allium sativum* (garlic) palliate the hepatopulmonary syndrome?" *Journal of Clinical Gastroenterology*, vol. 15, no. 3, pp. 248–250, 1992.
- [55] G. A. Abrams and M. B. Fallon, "Treatment of hepatopulmonary syndrome with *Allium sativum* L. (Garlic): a pilot trial," *Journal of Clinical Gastroenterology*, vol. 27, no. 3, pp. 232–235, 1998.
- [56] M. N. Sani, H. R. Kianifar, A. Kianee, and G. Khatami, "Effect of oral garlic on arterial oxygen pressure in children with hepatopulmonary syndrome," *World Journal of Gastroenterology*, vol. 12, no. 15, pp. 2427–2431, 2006.
- [57] B. K. De, D. Dutta, S. K. Pal, S. Gangopadhyay, S. D. Baksi, and A. Pani, "The role of garlic in hepatopulmonary syndrome: a randomized controlled trial," *Canadian Journal of Gastroenterology*, vol. 24, no. 3, pp. 183–188, 2010.
- [58] S. Nagae, M. Ushijima, S. Hatono et al., "Pharmacokinetics of the garlic compound S-allylcysteine," *Planta Medica*, vol. 60, no. 3, pp. 214–217, 1994.
- [59] D. D. Ku, T. T. Abdel-Razek, J. Dai, S. Kim-Park, M. B. Fallon, and G. A. Abrams, "Garlic and its active metabolite allicin produce endothelium- and nitric oxide-dependent relaxation in rat pulmonary arteries," *Clinical and Experimental Pharmacology and Physiology*, vol. 29, no. 1-2, pp. 84–91, 2002.
- [60] A. S. Mousa and S. A. Mousa, "Anti-angiogenesis efficacy of the garlic ingredient alliin and antioxidants: role of nitric oxide and p53," *Nutrition and Cancer*, vol. 53, no. 1, pp. 104–110, 2005.
- [61] N. Matsuura, Y. Miyamae, K. Yamane et al., "Aged garlic extract inhibits angiogenesis and proliferation of colorectal carcinoma cells," *Journal of Nutrition*, vol. 136, no. 3, pp. 842S–846S, 2006.
- [62] H. Nunes, D. Lebrec, M. Mazmanian et al., "Role of nitric oxide in hepatopulmonary syndrome in cirrhotic rats," *American Journal of Respiratory and Critical Care Medicine*, vol. 164, no. 5, pp. 879–885, 2001.
- [63] M. Maniscalco, M. Sofia, and T. Higenbottam, "Effects of an NO-synthase inhibitor L-NMMA in the hepatopulmonary syndrome," *Respiration*, vol. 68, no. 2, p. 226, 2001.
- [64] F. P. Gómez, J. A. Barberá, J. Roca, F. Burgos, C. Gistau, and R. Rodríguez-Roisin, "Effects of nebulized NG-nitro-L-arginine methyl ester in patients with hepatopulmonary syndrome," *Hepatology*, vol. 43, no. 5, pp. 1084–1091, 2006.
- [65] T. J. Diao, X. Chen, L. H. Deng et al., "Protective effect of nitric oxide on hepatopulmonary syndrome from ischemia-reperfusion injury," *World Journal of Gastroenterology*, vol. 18, no. 25, pp. 3310–3316, 2012.
- [66] P. Durand, C. Baujard, A. L. Grosse et al., "Reversal of hypoxemia by inhaled nitric oxide in children with severe hepatopulmonary syndrome, type 1, during and after liver transplantation," *Transplantation*, vol. 65, no. 3, pp. 437–439, 1998.
- [67] P. C. H. Hollman and M. B. Katan, "Dietary flavonoids: intake, health effects and bioavailability," *Food and Chemical Toxicology*, vol. 37, no. 9-10, pp. 937–942, 1999.
- [68] A. W. Boots, G. R. M. M. Haenen, and A. Bast, "Health effects of quercetin: from antioxidant to nutraceutical," *European Journal of Pharmacology*, vol. 585, no. 2-3, pp. 325–337, 2008.
- [69] J. Zeng, B. Yi, Z. Wang, J. Ning, X. Wang, and K. Lu, "Effect of annexin A2 on hepatopulmonary syndrome rat serum-induced proliferation of pulmonary arterial smooth muscle cells," *Respiratory Physiology & Neurobiology*, vol. 185, no. 2, pp. 332–338, 2013.
- [70] J. Tieppo, M. J. Cuevas, R. Vercelino, M. J. Tuñón, N. P. Marroni, and J. González-Gallego, "Quercetin administration ameliorates pulmonary complications of cirrhosis in rats," *Journal of Nutrition*, vol. 139, no. 7, pp. 1339–1346, 2009.
- [71] J. Tieppo, R. Vercelino, A. S. Dias et al., "Evaluation of the protective effects of quercetin in the hepatopulmonary syndrome," *Food and Chemical Toxicology*, vol. 45, no. 7, pp. 1140–1146, 2007.
- [72] D. Miljkovic, I. Cvetkovic, S. Stosic-Grujicic, and V. Trajkovic, "Mycophenolic acid inhibits activation of inducible nitric oxide synthase in rodent fibroblasts," *Clinical and Experimental Immunology*, vol. 132, no. 2, pp. 239–246, 2003.
- [73] M. C. Villarroel, M. Hidalgo, and A. Jimeno, "Mycophenolate mofetil: an update," *Drugs of Today*, vol. 45, no. 7, pp. 521–532, 2009.
- [74] S. Domhan, S. Muschal, C. Schwager et al., "Molecular mechanisms of the antiangiogenic and antitumor effects of mycophenolic acid," *Molecular Cancer Therapeutics*, vol. 7, no. 6, pp. 1656–1668, 2008.
- [75] H. Moreira Silva, G. Reis, M. Guedes et al., "A case of hepatopulmonary syndrome solved by mycophenolate mofetil (an inhibitor of angiogenesis and nitric oxide production)," *Journal of Hepatology*, vol. 58, no. 3, pp. 630–633, 2013.
- [76] Ş. Yilmaz, M. Dursum, F. Canoruç, K. Bayan, A. Karabulut, and H. Akay, "A severe (type II) hepatopulmonary syndrome in a patient with idiopathic portal hypertension and treatment with paroxetine," *Netherlands Journal of Medicine*, vol. 63, no. 11, pp. 448–452, 2005.

- [77] R. Iyer, G. Fetterly, A. Lugade, and Y. Thanavala, "Sorafenib: a clinical and pharmacologic review," *Expert Opinion on Pharmacotherapy*, vol. 11, no. 11, pp. 1945–1955, 2010.
- [78] C. C. Chang, C. L. Chuang, F. Y. Lee et al., "Sorafenib treatment improves hepatopulmonary syndrome in rats with biliary cirrhosis," *Clinical Science*, vol. 124, no. 7, pp. 457–466, 2013.
- [79] J. M. Theysohn, J. F. Schlaak, S. Müller et al., "Selective internal radiation therapy of hepatocellular carcinoma: potential hepatopulmonary shunt reduction after sorafenib administration," *Journal of Vascular and Interventional Radiology*, vol. 23, no. 7, pp. 949–952, 2012.
- [80] S. Krug, A. Sablotzki, S. Hammerschmidt, H. Wirtz, and H.-J. Seyfarth, "Inhaled iloprost for the control of pulmonary hypertension," *Vascular Health and Risk Management*, vol. 5, no. 1, pp. 465–474, 2009.
- [81] M. Gombert-Maitland and I. R. Preston, "Prostacyclin therapy for pulmonary arterial hypertension: new directions," *Seminars in Respiratory and Critical Care Medicine*, vol. 26, no. 4, pp. 394–401, 2005.
- [82] S. Krug, H.-J. Seyfarth, A. Hagendorff, and H. Wirtz, "Inhaled iloprost for hepatopulmonary syndrome: improvement of hypoxemia," *European Journal of Gastroenterology and Hepatology*, vol. 19, no. 12, pp. 1140–1143, 2007.
- [83] R. Vercelino, J. Tieppo, A. S. Dias et al., "N-acetylcysteine effects on genotoxic and oxidative stress parameters in cirrhotic rats with hepatopulmonary syndrome," *Basic and Clinical Pharmacology and Toxicology*, vol. 102, no. 4, pp. 370–376, 2008.
- [84] M. J. Krowka, E. R. Dickson, and D. A. Cortese, "Hepatopulmonary syndrome: clinical observations and lack of therapeutic response to somatostatin analogue," *Chest*, vol. 104, no. 2, pp. 515–521, 1993.
- [85] H. Ozyurt, B. Ozyurt, K. Koca, and S. Ozgocmen, "Caffeic acid phenethyl ester (CAPE) protects rat skeletal muscle against ischemia-reperfusion-induced oxidative stress," *Vascular Pharmacology*, vol. 47, no. 2-3, pp. 108–112, 2007.
- [86] Y. S. Song, E.-H. Park, G. M. Hur et al., "Caffeic acid phenethyl ester inhibits nitric oxide synthase gene expression and enzyme activity," *Cancer Letters*, vol. 175, no. 1, pp. 53–61, 2002.
- [87] A. Tekin, S. Türkyılmaz, T. Küçükartallar et al., "Effects of caffeic acid phenethyl ester (CAPE) on hepatopulmonary syndrome," *Inflammation*, vol. 34, no. 6, pp. 614–619, 2011.